Alzheimer's disease (AD) is pathologically defined by the presence of fibrillar amyloid β (Aβ)
peptide in extracellular senile plaques and tau filaments in intracellular neurofibrillary …

Purpose The development of blood biomarkers that reflect Alzheimer's disease (AD)
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …

The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease …

There is an unmet need to develop low-cost, rapid and highly multiplexed diagnostic
technology platforms for quantitatively detecting blood biomarkers to advance clinical …

The advent of proteomics offers an unprecedented opportunity to predict dementia onset.
We examined this in data from 52,645 adults without dementia in the UK Biobank, with 1,417 …

Alzheimer's disease causes a progressive dementia that currently affects over 35 million
individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no …

Recent evidence indicates that sensory and motor changes may precede the cognitive
symptoms of Alzheimer's disease (AD) by several years and may signify increased risk of …

Developing a single-domain assay to identify individuals at high risk of future events is a
priority for multi-disease and mortality prevention. By training a neural network, we …

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …

It is now well understood that once in contact with biological fluids, nanoscale objects lose
their original identity and acquire a new biological character, referred to as a protein corona …